Current Report Filing (8-k)
20 December 2022 - 9:30AM
Edgar (US Regulatory)
0001349929
false
--12-31
0001349929
2022-12-16
2022-12-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): December 16, 2022
VYANT
BIO, INC.
(Exact
Name of Company as Specified in its Charter)
Delaware |
|
001-35817 |
|
04-3462475 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
2
Executive Campus
2370
State Route 70, Suite 310
Cherry
Hill, NJ 08002
(Address
of Principal Executive Offices) (Zip Code)
Company’s
telephone number, including area code (201) 479-8126
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any
of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock |
|
VYNT |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the Company is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On
December 16, 2022, the Board of Directors of Vyant Bio, Inc. (the “Company”) approved an amendment (the “Amendment”)
to the Amended and Restated Bylaws (the “Bylaws”), of the Company to decrease the quorum requirement for stockholder meetings
from a majority to one-third of the voting power of the shares of the capital stock of the Company entitled to vote at a meeting, present
in person or represented by proxy.
The
foregoing summary of the Amendment set forth under this Item 5.03 does not purport to be complete and is qualified in its entirety by
reference to the complete text of the Amendment, which is attached hereto as Exhibit 3.1.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
As
described above, the following exhibits are furnished as part of this report:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
VYANT
BIO, INC. |
|
|
|
|
Date: |
December
19, 2022 |
By: |
/s/
John A. Roberts |
|
|
Name: |
John
A. Roberts |
|
|
Title: |
President
and Chief Executive Officer |
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Cancer Genetics Inc (NASDAQ): 0 recent articles
More Vyant Bio, Inc. News Articles